Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder

Abraham Pavlotsky; Abraham Eidelman; Frida Barak; Haim Alon; Yoav Horn

doi:10.1002/jso.2930410106

Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder

Abraham Pavlotsky, Abraham Eidelman, Frida Barak, Haim Alon, Yoav Horn

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2‐week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity‐related symptoms. Cystoscopic follow‐up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.

Original language	English
Pages (from-to)	9-11
Number of pages	3
Journal	Journal of Surgical Oncology
Volume	41
Issue number	1
DOIs	https://doi.org/10.1002/jso.2930410106
State	Published - 1 Jan 1989
Externally published	Yes

Keywords

diagnostic cystoscopy
mitomycin C
superficial bladder cancer
transurethral resection

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jso.2930410106

Cite this

@article{375d40484d114ebe9c42126042b6b2a8,

title = "Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder",

abstract = "We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2‐week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity‐related symptoms. Cystoscopic follow‐up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.",

keywords = "diagnostic cystoscopy, mitomycin C, superficial bladder cancer, transurethral resection",

author = "Abraham Pavlotsky and Abraham Eidelman and Frida Barak and Haim Alon and Yoav Horn",

year = "1989",

month = jan,

day = "1",

doi = "10.1002/jso.2930410106",

language = "English",

volume = "41",

pages = "9--11",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder

AU - Pavlotsky, Abraham

AU - Eidelman, Abraham

AU - Barak, Frida

AU - Alon, Haim

AU - Horn, Yoav

PY - 1989/1/1

Y1 - 1989/1/1

N2 - We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2‐week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity‐related symptoms. Cystoscopic follow‐up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.

AB - We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2‐week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity‐related symptoms. Cystoscopic follow‐up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.

KW - diagnostic cystoscopy

KW - mitomycin C

KW - superficial bladder cancer

KW - transurethral resection

UR - http://www.scopus.com/inward/record.url?scp=0024561733&partnerID=8YFLogxK

U2 - 10.1002/jso.2930410106

DO - 10.1002/jso.2930410106

M3 - Article

AN - SCOPUS:0024561733

VL - 41

SP - 9

EP - 11

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -

Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this